This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

MELA Sciences To Host Investor Meeting In Conjunction With Melanoma Monday On May 6th 2013 In New York

IRVINGTON, N.Y., April 18, 2013 (GLOBE NEWSWIRE) -- MELA Sciences, Inc. (Nasdaq:MELA), the medical device company that has developed MelaFind ®, today announced that it will be hosting a meeting for investors and analysts in conjunction with Melanoma Monday on May 6, 2013 from 10:00am to 11:00am Eastern time, in New York City.

Joseph V. Gulfo, MD, the Company's President and CEO, will host the meeting and will provide a brief introduction and business update. He will then moderate a panel discussion and presentations from leading dermatologists Mark S. Nestor, MD, PhD, Voluntary Associate Professor of the Department of Dermatology and Cutaneous Surgery at the University of Miami Miller School of Medicine, and Dr. Gary Goldenberg, MD, Medical Director, Dermatology Faculty Practice at The Mount Sinai Medical Center, Assistant Professor of Dermatology and Pathology at the Mount Sinai School of Medicine. The clinicians will discuss their current practice patterns, the clinical utility of MelaFind and how they are incorporating it into their practice, as well as the product's potential market opportunity. Following the presentations, there will be a question and answer session.

A live audio webcast of the MELA Sciences Investor Meeting will be accessible through the investor relations section of Company's website at www.melasciences.com. An archived edition of the presentation will be available later that day and will be available for at least 30 days afterward.

About MELA Sciences, Inc.

MELA Sciences is a medical device company focused on the commercialization of its flagship product, MelaFind ®, and its further design and development. MelaFind is a non-invasive tool to provide additional information to dermatologists during melanoma skin examinations. The device uses light from visible to near-infrared wavelengths to evaluate skin lesions up to 2.5 mm beneath the skin. The device provides information on a lesion's level of morphologic disorganization to provide additional objective information that may be used by dermatologists in the biopsy decision-making process. MelaFind has been approved by the U.S. Food and Drug Administration for use in the U.S. In addition, MelaFind has received CE Mark approval and is approved for use in the European Union.

For more information on MELA Sciences, visit www.melasciences.com .

CONTACT: For Investors
         Lynn Pieper
         Westwicke Partners
         415-202-5678
         
         For Media
         Erica Sperling
         Rpr Marketing Communications
         212-317-1462

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,091.32 +53.35 0.30%
S&P 500 2,114.48 +5.56 0.26%
NASDAQ 5,055.8560 -4.39 -0.09%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs